These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 17376172)

  • 1. Total CD34+ cells per 10 HPF in bone marrow trephines of patients with chronic myeloid leukaemia correlates with probability of complete cytogenetic response following imatinib treatment.
    Elliot V; Marin D; Horncastle D; Elderfield K; Howard J; Apperley JF; Lampert IA; Naresh KN
    Histopathology; 2007 May; 50(6):810-2. PubMed ID: 17376172
    [No Abstract]   [Full Text] [Related]  

  • 2. Peripheral blood progenitor cell collection in chronic myeloid leukemia patients with complete cytogenetic response after treatment with imatinib mesylate.
    Perseghin P; Gambacorti-Passerini C; Tornaghi L; Dassi M; Pioltelli P; Parma M; Colnaghi F; Giudici G; Elli E; Fumagalli M; Ponchio L; Biondi A; Pogliani EM
    Transfusion; 2005 Jul; 45(7):1214-20. PubMed ID: 15987369
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ST1571 (imatinib mesylate) reduces bone marrow cellularity and normalizes morphologic features irrespective of cytogenetic response.
    Hasserjian RP; Boecklin F; Parker S; Chase A; Dhar S; Zaiac M; Olavarria E; Lampert I; Henry K; Apperley JF; Goldman JM
    Am J Clin Pathol; 2002 Mar; 117(3):360-7. PubMed ID: 11888075
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Imatinib-related bone marrow aplasia after complete cytogenetic response in chronic myeloid leukemia.
    Khan KA; Junaid A; Siddiqui NS; Mukhtar K; Siddiqui S
    J Coll Physicians Surg Pak; 2008 Mar; 18(3):176-8. PubMed ID: 18460249
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Functional activity of CD34-positive cells in chronic myeloid leukemia patients with different response to imatinib therapy.
    Sviezhentseva IO; Perekhrestenko TP; Bilko DI; Gordienko AI; Diachenko MV; Dyagil IS
    Exp Oncol; 2015 Mar; 37(1):70-2. PubMed ID: 25804236
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bone marrow with gelatinous transformation associated with residual disease in imatinib mesylate-treated chronic myelogenous leukaemia (CML).
    Thakral B; Higa B; Venkataraman G; Velankar MM
    Pathology; 2012 Jan; 44(1):59. PubMed ID: 22157697
    [No Abstract]   [Full Text] [Related]  

  • 7. Promyelocytic blast crisis of chronic myeloid leukemia during imatinib treatment.
    Chung HJ; Chi HS; Cho YU; Park CJ; Seo EJ; Kim KH; Lee JH
    Ann Clin Lab Sci; 2008; 38(3):283-6. PubMed ID: 18715859
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Proposal of a morphologic bone marrow response score for imatinib mesylate treatment in chronic myelogenous leukemia.
    Lugli A; Ebnoether M; Cogliatti SB; Gratwohl A; Passweg J; Hess U; Korte W; Hawle H; Tinguely M; Borisch B; Mach-Pascual S; Von Juergensonn S; Tichelli A; Dirnhofer S
    Hum Pathol; 2005 Jan; 36(1):91-100. PubMed ID: 15712187
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hematological and molecular response evaluation of CML patients on imatinib.
    Gupta A; Prasad K
    J Assoc Physicians India; 2007 Feb; 55():109-13. PubMed ID: 17571739
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bone marrow changes in chronic myelogenous leukaemia after long-term treatment with the tyrosine kinase inhibitor STI571: an immunohistochemical study on 75 patients.
    Thiele J; Kvasnicka HM; Schmitt-Graeff A; Kriener S; Engels K; Staib P; Ollig ES; Keller C; Fokkema S; Griesshammer M; Waller CF; Ottmann OG; Hansmann ML
    Histopathology; 2005 May; 46(5):540-50. PubMed ID: 15842636
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A half-log increase in BCR-ABL RNA predicts a higher risk of relapse in patients with chronic myeloid leukemia with an imatinib-induced complete cytogenetic response.
    Press RD; Galderisi C; Yang R; Rempfer C; Willis SG; Mauro MJ; Druker BJ; Deininger MW
    Clin Cancer Res; 2007 Oct; 13(20):6136-43. PubMed ID: 17947479
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Circumventing resistance to imatinib therapy in chronic myeloid leukemia].
    Minami Y; Naoe T
    Gan To Kagaku Ryoho; 2009 Apr; 36(4):544-7. PubMed ID: 19381024
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CD34+/Ph+ cells are still detectable in chronic myeloid leukemia patients with sustained and prolonged complete cytogenetic remission during treatment with imatinib mesylate.
    Bocchia M; Ippoliti M; Gozzetti A; Abruzzese E; Calabrese S; Amabile M; Pirrotta MT; Crupi R; Tozzuoli D; Trawinska MM; Defina M; Martinelli G; Lauria F
    Leukemia; 2008 Feb; 22(2):426-8. PubMed ID: 17690698
    [No Abstract]   [Full Text] [Related]  

  • 14. Imatinib mesylate in the treatment of chronic myeloid leukemia: a local experience.
    Bee PC; Gan GG; Teh A; Haris AR
    Med J Malaysia; 2006 Dec; 61(5):547-52. PubMed ID: 17623954
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Functional integrity in vitro of hematopoietic progenitor cells from patients with chronic myeloid leukemia that have achieved hematological remission after different therapeutic procedures.
    Chávez-González A; Ayala-Sánchez M; Sánchez-Valle E; Ruiz-Sánchez E; Arana-Trejo RM; Vela-Ojeda J; Mayani H
    Leuk Res; 2006 Mar; 30(3):286-95. PubMed ID: 16111748
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Promyelocytic blast crisis of chronic myelogenous leukemia during imatinib treatment.
    Gozzetti A; Bocchia M; Calabrese S; Pirrotta MT; Crupi R; Raspadori D; Lauria F
    Acta Haematol; 2007; 117(4):236-7. PubMed ID: 17308370
    [No Abstract]   [Full Text] [Related]  

  • 17. Percentage of CD34 cells in a minimum 500-cell count in bone marrow trephines of patients with chronic myeloid leukaemia provides the best correlation with aspirate blast count.
    Elliot V; Marin D; Horncastle D; Elderfield K; Apperley JF; Lampert IA; Naresh K
    Br J Haematol; 2005 Aug; 130(3):460-1. PubMed ID: 16042700
    [No Abstract]   [Full Text] [Related]  

  • 18. Abnormal phenotype of bone marrow plasma cells in patients with chronic myeloid leukemia undergoing therapy with Imatinib.
    Carulli G; Cannizzo E; Ottaviano V; Cervetti G; Buda G; Galimberti S; Baratè C; Marini A; Petrini M
    Leuk Res; 2010 Oct; 34(10):1336-9. PubMed ID: 20149455
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Achievement of complete molecular responses in late chronic phase chronic myeloid leukaemia patients treated with pulsed imatinib while in minimal residual disease.
    Breccia M; Cannella L; Stefanizzi C; Santopietro M; De Cuia R; Diverio D; Alimena G
    Leuk Res; 2009 May; 33(5):645-8. PubMed ID: 19062090
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interferon in chronic myeloid leukaemia: past and future.
    Guilhot F; Roy L; Saulnier PJ; Guilhot J
    Best Pract Res Clin Haematol; 2009 Sep; 22(3):315-29. PubMed ID: 19959083
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.